Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia
AssigneeEndorecherche, Inc.
InventorFernand Labrie
Life of this patent
Estimating the term…
Abstract
A combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia in susceptible warm-blooded animals which comprises administering a combination of two or more compounds selected from the group consisting of an inhibitor of 5α-reductase activity, an anti-estrogen, an inhibitor of aromatase activity, an inhibitor of 17β-hydroxysteroid dehydrogenase activity and, in some cases, an anti-androgen and/or an LHRH agonist. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such compositions are disclosed.
Claims18
A method of treating benign prostatic hyperplasia comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of 17β-hydroxysteroid dehydrogenase and at least one compound selected from the group consisting of an inhibitor of aromatase and an inhibitor of 5α-reductase.
A method of treating benign prostatic hyperplasia comprising administering to a patient in need of such treatment, a therapeutically effective amount of an antiestrogen and at least one compound selected from the group consisting of an inhibitor of 17β hydroxysteroid dehydrogenase and an inhibitor of 5α-reductase.
A kit comprising a plurality of separate containers, wherein at least one of said containers contains an inhibitor of 17β-hydroxysteroid dehydrogenase and at least one other of said containers contains a compound selected from the group consisting of an inhibitor of aromatase and an inhibitor of 5α-reductase.
A kit comprising a plurality of separate containers, wherein at least one of said containers contains an antiestrogen and at least one other of said containers contains at least one compound selected from the group consisting of an inhibitor of 5α-reductase and an inhibitor of 17β-hydroxysteroid dehydrogenase.
A pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable diluent carrier or excipient, a therapeutically effective amount of an inhibitor of 17β hydroxysteroid dehydrogenase, and a therapeutically effective amount of at least one compound selected from the group consisting of an inhibitor of aromatase and an inhibitor of 5α-reductase.
A pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable diluent carrier or excipient, a therapeutically effective amount of an inhibitor of antiestrogen and a therapeutically effective amount of at least one compound selected from the group consisting of an inhibitor of 5α-reductase and an inhibitor of 17β hydroxysteroid dehydrogenase.
Dependencies are inferred from the claim text.